用埃多克萨班长期预防二次中风:SATES研究的长期随访
Irene Scala1,2, Simone Bellavia1, Pier Andrea Rizzo1
1School of Medicine and Surgery, Catholic University of Sacred Heart, Largo Francesco Vito, 1, 00168 Rome, Italy.
Brain sciences
|November 25, 2023
概括
在缺血性中风患者中长期使用埃多克萨班显示出良好的安全性和有效性. 埃多克萨班治疗显示出最佳的持续率,在延长的随访期间,主要出血和血栓塞栓事件的发病率较低.
科学领域:
- 心脏病学 心脏病学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 由于最近引入edoxaban,对edoxaban的长期数据有限.
- 评估长期的安全性和疗效对于临床实践至关重要.
研究的目的:
- 评估edoxaban的长期安全性,重点关注重大出血事件.
- 评估血栓栓塞事件的发生率和随着时间的推移而持续治疗edoxaban.
主要方法:
- 观测队列研究的设计.
- 包括先前研究中的缺血性中风患者.
- 通过训练有素的调查人员进行结构化的电话采访来收集数据.
主要成果:
- 总共有63名患者 (平均年龄81岁) 接受了平均4.4年的随访.
- 报告有一次主要的脑外出血 (1.6%),没有脑出血.
- 发生了6次血栓塞栓事件 (7.9%),包括中风,TIA和心肌梗塞.
- 在随访期间,有13名患者 (20.6%) 停止服用埃多克萨班.
结论:
- 埃多克萨班似乎是缺血性中风的安全有效的长期治疗选择.
- 高持续率表明耐受性良好,患者在三年内坚持埃多克萨班治疗.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
711
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
711
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
532
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
532


